Myocarditis manifestations in dengue cases: A systematic review and meta-analysis

Sandeep, Mokanpally; Padhi, Bijaya Kumar; Yella, Sree Sudha Tanguturi; Venkatesan, R.; Sasanka, K S B S Krishna; Satapathy, Prakasini; Mohanty, Aroop; Al‐Tawfiq, Jaffar A.; Iqhrammullah, Muhammad; Rabaan, Ali A.; Kabi, Ankita; Sah, Sanjit; Rustagi, Sarvesh; Al‐qaim, Zahraa Haleem; Barboza, Joshuan J.; Waheed, Yasir; Harapan, Harapan; Sah, Ranjit

doi:10.1016/j.jiph.2023.08.005

Cited by 7 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statistical significance in the stratification analysis was determined using Z-statistics. The statistical analysis adhered to recommendations from previous studies [24][25][26].…”

Section: Discussionmentioning

confidence: 99%

Global Rate of Willingness to Volunteer Among Medical and Health Students During Pandemic: Systemic Review and Meta-Analysis

Mahsusi,

Hudaa,

Nuryani

et al. 2024

JMIR Med Educ

Self Cite

View full text Add to dashboard Cite

Background During health crises such as the COVID-19 pandemic, shortages of health care workers often occur. Recruiting students as volunteers could be an option, but it is uncertain whether the idea is well-accepted. Objective This study aims to estimate the global rate of willingness to volunteer among medical and health students in response to the COVID-19 pandemic. Methods A systematic search was conducted on PubMed, Embase, Scopus, and Google Scholar for studies reporting the number of health students willing to volunteer during COVID-19 from 2019 to November 17, 2023. The meta-analysis was performed using a restricted maximum-likelihood model with logit transformation. Results A total of 21 studies involving 26,056 health students were included in the meta-analysis. The pooled estimate of the willingness-to-volunteer rate among health students across multiple countries was 66.13%, with an I2 of 98.99% and P value of heterogeneity (P-Het)<.001. Removing a study with the highest influence led to the rate being 64.34%. Our stratified analyses indicated that those with older age, being first-year students, and being female were more willing to volunteer (P<.001). From highest to lowest, the rates were 77.38%, 77.03%, 65.48%, 64.11%, 62.71%, and 55.23% in Africa, Western Europe, East and Southeast Asia, Middle East, and Eastern Europe, respectively. Because of the high heterogeneity, the evidence from this study has moderate strength. Conclusions The majority of students are willing to volunteer during COVID-19, suggesting that volunteer recruitment is well-accepted.

show abstract

“…Statistical significance in the stratification analysis was determined using Z-statistics. The statistical analysis adhered to recommendations from previous studies [24][25][26].…”

Section: Discussionmentioning

confidence: 99%

Global Rate of Willingness to Volunteer Among Medical and Health Students During Pandemic: Systemic Review and Meta-Analysis

Mahsusi,

Hudaa,

Nuryani

et al. 2024

JMIR Med Educ

Self Cite

View full text Add to dashboard Cite

show abstract

“…The adherence rate was calculated by multiplying the pooled proportion by 100%. The pooled proportion was obtained from a meta-analysis using Jamovi v.2.3.21 (https://www.jamovi.org/ accessed on 25 October 2023), as suggested by previous studies [24,25]. Pooled estimates were based on the outcome of the Phase II clinical trial.…”

Section: Discussionmentioning

confidence: 99%

Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

Tsurayya,

Nazhifah,

Pirwanja

et al. 2024

Children

Self Cite

View full text Add to dashboard Cite

Growth hormone treatment has effectively restored normal growth in children with growth hormone deficiency (GHD); however, it poses challenges in compliance with a daily growth hormone injection regimen, leading to low adherence and persistence rates. Once-weekly Somapacitan is a potential alternative for treating children with GHD. This study aimed to evaluate the efficacy, safety, and adherence of once-weekly subcutaneous Somapacitan compared to daily growth hormone injection in prepubertal children with GHD. A search for the published records was carried out on 17 October 2023 utilizing the searching feature available on PubMed, Embase, and Scopus. Primary study outcomes included (1) efficacy, measured by height velocity (HV), standard deviation score (SDs), height SDs, insulin-like growth factor-SDs (IGF-I SDs), and bone age vs. chronological age ratio (BA vs. CA); (2) safety, assessed through adverse events and injection site reactions; and (3) adherence, determined by the percentage of the sample completing treatments. Secondary outcomes evaluated disease burden scores, divided into three subgroup domains: emotional well-being, physical functional, and social well-being scores. We retrieved 6 studies that were eligible for the systematic review (417 versus 186 for intervention and control, respectively). Only 2 of the total included studies were eligible for pooled analysis (175 versus 82 for intervention and control, respectively). The efficacy profile of Somapacitan was similar to daily growth hormones, indicated by HV (mean difference (MD = 0.04; p = 0.96), HV SDs (MD = −0.71; p = 0.09), height SDs (MD = 0.11; p = 0.69), IGF-I SDs (MD = 0.06; p = 0.70), and CA vs. BA (MD = 0.67; p = 0.70)), demonstrated similar and non-inferior outcomes. Treatment adherence is 3 times higher in the Somapacitan group as compared to control (OR = 3.02; p = 0.03) with adherence rates reaching 95% and 88% for Somapacitan and Norditropin®, respectively. The disease burden measurement is similar in Somapacitan and daily growth hormones (MD = −0.62; p = 0.83), as indicated by the Growth Hormone Deficiency–Child Impact Measure. In almost all outcomes, the level of confidence is strong. The confidence level in the data is generally strong, but for CA vs. BA and the subgroup of severe adverse events with heterogeneity >50%, the confidence level is moderate. Although the efficacy and safety profiles of Somapacitan were found to be similar to those of daily growth hormones, a reduced frequency of once-weekly Somapacitan injections led to increased adherence. PROSPERO registration: CRD42023473209.

show abstract

“…The pooled prevalence of dengue-induced myocarditis in the studied population was nearly 24.0%. 45 However, the sequelae of other viral infections (such as influenza, Dengue, or Ebola) typically entail a shorter duration and milder symptomatology. The clinical similarities with long COVID suggest an autoimmune reactive inflammatory response associated with the release of autoantigens from activated or dying neutrophils, an elevated neutrophil-to-lymphocyte ratio, and the formation of neutrophil extracellular traps.…”

Section: Relation To Other Studiesmentioning

confidence: 99%

Increased risk of new‐onset cardiovascular disease after COVID‐19: A systematic review and meta‐analysis of 14 cohorts

Sun,

Yuan,

Lai

et al. 2024

Reviews in Medical Virology

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) are common in long COVID, yet the associated risk remains uncertain. We aimed to quantify the risk of new‐onset cardiovascular diseases after COVID‐19. We searched PubMed, Embase, and Web of Science from inception up to October 2022. Cohort studies that provided information on the number, proportion, or relative risks (RR) of cardiovascular diseases after COVID‐19 were included. Paired reviewers independently screened studies, extracted data, and assessed the risk of bias. We performed random‐effects models meta‐analyses to calculate RR and corresponding 95% confidence interval (95%CI), and conducted subgroup analyses and meta‐regression to explore the potential risk factors. Absolute effects were calculated to facilitate interpretation. The Grading of Recommendations, Assessment, Development and Evaluation approach was used to assess the certainty of evidence. Outcomes of interest were any CVD, major adverse cardiovascular events (MACE), arrhythmias, heart failure, myocarditis, and thrombotic events. Fourteen cohort studies with over 25.37 million participants were included. The results showed a 2.42 times higher risk of any CVD (RR = 2.42, 95% CI: 1.24–4.71; 51 more per 1000), a 95% higher risk of MACE (RR = 1.95, 95% CI: 1.59–2.40; 4 more per 1000), a 61% higher risk of arrhythmias (RR = 1.61, 95% CI: 1.42–1.83; 12 more per 1000), a 71% higher risk of heart failure (RR = 1.71, 95% CI: 1.33–2.21; 2 more per 1000), a 5 times higher risk of myocarditis (RR = 5.06, 95% CI: 3.78–6.77; 4 more per 1000), and a 2.49 times higher risk of thrombotic events (RR = 2.49, 95% CI: 1.22–5.06; 6 more per 1000) associated with COVID‐19. Besides, for thrombotic events, a statistically significant subgroup effect was observed in male participants compared to females (Pinteraction = 0.008). The certainty of evidence was high for myocarditis, but low or very low for other outcomes. The results clearly showed varying degrees of elevated new‐onset CVD risk in post‐COVID‐19 individuals. Additionally, our findings suggest that male patients face a higher risk of thrombotic events. However, the differences in pooled results between studies, and the over‐precision due to the large sample size of the included studies resulted in high heterogeneity of exceeding 90% in most outcomes, which led to low certainty of evidence.

show abstract

Myocarditis manifestations in dengue cases: A systematic review and meta-analysis

Cited by 7 publications

References 44 publications

Global Rate of Willingness to Volunteer Among Medical and Health Students During Pandemic: Systemic Review and Meta-Analysis

Global Rate of Willingness to Volunteer Among Medical and Health Students During Pandemic: Systemic Review and Meta-Analysis

Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

Increased risk of new‐onset cardiovascular disease after COVID‐19: A systematic review and meta‐analysis of 14 cohorts

Contact Info

Product

Resources

About